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1.0 Introduction 
 
In May 2002, the United States Department of Energy (DOE) signed Assistance 
Instrument Number DE-FC09-02CH11109 with the Medical University of South 
Carolina (MUSC) to support the Environmental Biosciences Program (EBP).  This 
funding instrument replaces DOE Assistance Instrument Number DE-FC02-98CH10902. 
 
EBP is an integrated, multidisciplinary scientific research program, employing a range of 
research initiatives to identify, study and resolve environmental health risks.  These 
initiatives are consistent with the MUSC role as a comprehensive state-supported health 
sciences institution and with the nation’s need for new and better approaches to the 
solution of a complex and expansive array of environment-related health problems. 
 
The intrinsic capabilities of a comprehensive health sciences institution enable MUSC to 
be a national resource for the scientific investigation of environmental health issues.  
EBPs success as a nationally prominent research program is due, in part, to its ability to 
task-organize scientific expertise from multiple disciplines in addressing these complex 
problems 
 
Current research projects have focused EBP talent and resources on providing the 
scientific basis for risk-based standards, risk-based decision making and the accelerated 
clean-up of widespread environmental hazards.  These hazards include trichloroethylene 
and low-dose ionizing radiation.  Work on the trichloroethylene research projects has 
been slowed as a result of funding uncertainties.  The impact of these funding 
uncertainties has been discussed with the DOE.  Plans for restructuring the performance 
schedule of the trichloroethylene projects have been submitted to the department.  A 
project is also being conducted in the use of geographical information system technology 
to analyze population health risks related to environmental hazards as a tool for risk-
based decision-making. 
 
Questions, comments or requests for further information concerning the activities under 
this cooperative agreement can be forwarded to Dr. Lawrence C. Mohr in the EBP office 
of the Medical University of South Carolina at (843) 792-1532. 
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1.1 Summary and Significance of Year Two Projects 
 
Toxicology 
 
• Trichloroethylene (TCE) is the most prevalent and widespread chemical 
contaminant at DOE sites.  TCE is regulated as a human carcinogen based upon 
its hepatocarcinogenicity in a crude mouse model.  Very little is known about the 
molecular mechanisms of carcinogenesis and the human health effects of TCE.  
MUSC has developed a comprehensive research program on the molecular 
mechanisms of disease pathogenesis and the human health effects of TCE to 
better understand the risks to workers at DOE sites.  Through this research 
program, MUSC helps to ensure that TCE risk assessment and remediation 
activities are based upon sound science. 
 
Risk Assessment 
 
• The adverse health effects of both ionizing and non-ionizing radiation are of 
concern to DOE and the public.  Many important questions about the adverse 
human health effects of low-dose and low-dose rate radiation exposures remain 
unanswered – especially with respect to cancer risks.  MUSC has developed a 
comprehensive research program for the study of the effects of low-dose and low-
dose rate radiation exposures on human health.  
 
• Population risk studies in areas surrounding DOE sites are of utmost importance 
to the department and to the citizens who live in these areas.  The Savannah River 
Region Health Information System is a very important national, regional, and 
DOE resource for the study of population health effects in the area surrounding 
the Savannah River Site.  In conjunction with the Savannah River Region Health 
Information System, MUSC has developed an extremely powerful Geographical 
Information System in which databases containing health, environmental, 
demographic and socioeconomic data can be integrated and analyzed for specific 
population health risks. 
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1.2 Program Expenditures 
 
EBP Expenditure Summary  
 
The table below reflects expenditures by budgeted category recorded for the period  
January 2007 through March 2007 and total life-to-date for Cooperative Agreement 
CH11109.   
 
 
 
Budget Category  Current Period                         LTD 
    (Dollars in thousands) 
Personnel             $ 144    
Supplies          .15          
Travel         1.0                                       
Other           .5                                  
Subcontract                                  -                                    
Equipment                              -                                       
Total Direct Costs                     146                                                       $ 6,780 
F & A                   80                                                              2,528                    
Total              $ 227                                                           $ 9,308 
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2.0 Program Management and Development Office 
 
The mission of the Program Management Office is to ensure that all projects of the 
cooperative agreement achieve their stated goals and objectives and are carried out in an 
efficient and cost-effective manner.  The executive leadership of the program has adopted 
a strategy-focused management approach that carefully aligns the resources and core 
competencies of the program with research priorities developed in coordination with 
DOE.  Specific Program Management responsibilities include workplan development, 
budget formulation, task organization of multidisciplinary research teams, financial 
management, progress reporting and program review. 
 
The Program Office reports to the Office of the Vice President for Academic Affairs and 
Provost.  Key faculty and staff members involved in Program Management are as 
follows: 
 
Principal Investigator and Director:  Lawrence C. Mohr, Jr., M.D. 
Associate Director for Program Development: John B. Dunbar, Dr. P.H. 
Associate Director for Administration 
and Finance: Gail C. Brubaker, B.S. 
Co-Principal Investigator, Environmental    
Toxicology:      David Jollow, Ph.D. 
Co-Principal Investigator, Environmental    
Epidemiology and Risk Assessment:   David G. Hoel, Ph.D.   
Fiscal Analyst:     Anita G. Jefferson, B.S.  
Administrative Coordinator:    Jill Canaday 
Administrative Specialist:    Percilla E. Coaxum 
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3.0 Scientific Research 
 
3.1 Environmental Toxicology Research Projects 
 
 
3.1.1 Characterization of Species Differences in Trichloroethylene – Induced 
Peroxisome Proliferation and Hepatocyte Replication 
 
Project Director:     JoEllyn M. McMillan, Ph.D. 
 
Executive Summary 
 
The hepatocarcinogenicity of trichloroethylene (TCE) is thought to be related to the 
ability of its metabolites, trichloroacetic acid (TCA) and dichloroacetic acid (DCA), to 
induce peroxisome proliferative and/or hepatocyte mitogenesis in B6C3F1 mice and rats.  
Humans are considered to be less sensitive to TCE, but their susceptibility to peroxisome 
proliferation and hepatocyte mitogenesis is largely unknown.  The relative susceptibility 
of human vs. B6C3F1 mouse hepatocytes to peroxisome proliferation is of key 
importance for the use of mechanistic information in the reassessment of the carcinogenic 
risk posed by environmental TCE. Of importance, the role of the peroxisome proliferator 
activated receptor a (PPARa) in the mitogenic response is unknown. It is believed that 
differences in the levels or activity of PPARa between humans and rodents is important 
in the relative insensitivity of human hepatocytes to traditional peroxisome proliferators.  
Thus, defining the role of PPARa in the mitogenic response and delineating differences in 
PPARa activity in humans vs. rodents would contribute key mechanistic information for 
assessing the hepatocarcinogenic risk posed to humans by TCE exposure. The overall 
goal of this proposal is two fold: (1) to enhance our understanding of the epigenetic basis 
for TCE-induced hepatocarcinogenicity; and (2) to improve the assessment of relative 
risk of human vs. the B6C3F1 mouse hepatocarcinogenicity.  
 
Relevance 
  
The ability of peroxisome proliferators to induce peroxisomal and non-peroxisomal 
enzymes, the mitogenic activity of these compounds and their hepatocarcinogenic 
potential varies among species and is dependent upon the particular chemical agent being 
used. The proposed studies will provide valuable mechanistic data for determining the 
relevance of the B6C3F1 mouse model for assessing the hepatocarcinogenic potential in 
humans of TCE and other peroxisome proliferators.  The studies will provide a 
quantitative comparison of the relative responsiveness of human versus mouse and rat 
hepatocytes to peroxisome-proliferator-induced changes in activities and levels of key 
proteins and mRNAs. 
 
Objective 
 
The hepatocarcinogenicity of TCE is believed to be related to the ability of its 
metabolites, TCA and DCA, to induce peroxisome proliferative and mitogenic 
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activity in B6C3F1 mice and rats.  Humans are considered to be less sensitive, but 
their susceptibility to peroxisome proliferation and mitogenesis is largely unknown.  
The role of PPARa in peroxisomal enzyme induction in rodents is well documented.  
However its regulation of other non-peroxisomal genes is less understood.  
Differences in the levels and activity of this transcription factor have been observed 
between human and rodent liver.  Thus determining the role of PPARa activation in 
both the peroxisomal and mitogenic responses in human and rodent hepatocytes is 
important in assessing the relative hepatocarcinogenic risk to humans of TCE 
exposure.  To this end our specific aims are as follows. 
 
Specific Aim 1. To develop sensitive and selective approaches to measure the 
peroxisome proliferative and mitogenic responses in cultured liver cells 
 
Specific Aim 2. To elucidate the mechanism for the short-term in vivo hepatocyte 
replication response 
 
Specific Aim 3. To determine the involvement of the peroxisome proliferator 
activated receptor a (PPARa) in peroxisomal and cell replicative events in rodent and 
human hepatocytes. 
 
Quarterly Accomplishments 
 
Work on this project has been suspended as a result of funding uncertainties.  Significant 
accomplishments to date include the development of experimental systems to conduct the 
following studies:  (1) metabolism of chloral hydrate by human hepatocytes and analysis 
of metabolic products by GC headspace analysis, (2) isolation of genomic DNA from 
human hepatocytes for ALDH and ADH genotyping, (3) genotyping of ALDH and ADH 
using genomic DNA from human hepatocytes. 
 
Plans are in place for further studies on the anti-apoptotic effect of dihalogenated 
acetates, including dichloroacetate, on hepatocytes from B6C3F1 mouse, rat and human 
liver. 
 
Performance Schedule and Status of Aims 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims are anticipated. 
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3.1.2 Effects of Trichloroethylene Metabolites on Hepatic Cell-Cycle Regulatory 
Proteins and Transcription Factors  
 
Project Director:        David T. Kurtz, Ph.D. 
 
Executive Summary 
 
This project explores the hypothesis that the epigenetic carcinogenicity of TCE results 
from the mitogenic activity of its metabolites. Mitogenesis may occur either via the 
peroxisomal response or by an independent mechanism. There are two specific research 
objectives: to determine how TCE metabolites cause increased cell growth and division 
in the liver and to develop quantitative tools to allow direct comparison of the 
responsiveness of humans vs. the laboratory rodent. The experimental approach will 
utilize cultured hepatocytes the B6C3F1 mouse, Long Evans and Sprague-Dawley rats, 
and long-term cultures of human hepatocytes, which have retained their differentiated 
properties. The ability of TCE and/or its metabolites to induce: cdk mRNAs and proteins; 
cyclin mRNAs and proteins; CKI mRNAs and proteins; and cyclin/cdk activity will be 
assessed. The activation of transcription factors associated with cell division (AP1, NF 
kappaB, E2F) and the inactivation of transcription factors associated with the suppression 
of cell division (C/EBP) will also be determined. To determine the importance of the 
peroxisome proliferator activated receptor (PPAR) in these inductions, the studies will 
also be carried out on hepatocytes from PPAR alpha -/- ("knockout") mice. These studies 
will provide valuable insight into the molecular basis of the non-genotoxic carcinogenic 
effects of TCE and related hazardous compounds. Furthermore, the measurements of cell 
cycle regulatory protein activity, and of transcription factors associated with cell 
proliferation, may prove to be an accurate biomarker for hepatocarcinogenesis. 
 
Relevance 
 
Trichloroethylene is a widespread contaminant at DOE sites. The toxicity of this 
compound to humans continues to be controversial. The studies outlined above should 
provide specific evidence for or against the hepatotoxicity of TCE. 
 
Objective 
 
The scientific problem being addressed in this proposal is the molecular basis for the 
hepatocarcinogenicity of TCE metabolites. The general approach will be a 
combination of biochemical, molecular biological, and cell biological techniques. To 
this end our specific aims are as follows. 
 
Specific Aim 1. To determine the molecular mechanism(s) by which TCE 
metabolites can serve as priming agents for mitogenesis in rodent hepatocytes and to 
determine if this effect can occur in human hepatocytes.  
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Specific Aim 2. To identify the effects of TCE metabolites on signal transduction 
cascades which may affect cell division in hepatocytes  
 
Specific Aim 3. To determine the effects of TCE metabolites on the activity of 
hepatocyte transcription factors which regulate cell division, and whether these effects 
require PPAR. 
 
Quarterly Accomplishments 
 
Work on this project has been suspended as a result of funding uncertainties.  Significant 
accomplishments to date include: 
 
1 We have characterized the effects of DCA and TCA in inducing beta 
catenin/TCF binding to DNA in rodent liver. 
 
2 We have examined the effects of DCA and TCA in inducing beta catenin 
nuclear translocation in human hepatoma cells. 
 
Performance Schedule and Status of Aims 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims are anticipated. 
 
 
3.1.3 Human and Rodent Renal Proximal Tubular Cells as Model Systems to 
Study the Toxicity and Elimination of Trichloroethylene Metabolites 
 
Project Director:     Douglas Sweet, Ph.D. 
 
Executive Summary 
 
A growing body of evidence suggests that trichloroethylene (TCE) exposure induces 
hepatocellular carcinoma, nephrotoxicity, and nephrocarcinogenicity in rats.  Further 
research has indicated that it is not the parent compound, TCE, but rather several of its 
metabolites, including trichloroacetic acid (TCA), dichloroacetic acid (DCA), and 1,2-
dichlorovinyl-L-cysteine (DCVC) that are the causative agents of the associated renal and 
hepatic toxicities.  The kidney and liver are target organs because they actively remove 
organic anions from the circulation and are therefore subject to high levels of 
accumulation of these negatively charged metabolites.  In the case of TCE, metabolite 
formation, particularly at drinking water levels, is extremely rapid and target tissue 
exposure is largely determined by the relative rates of formation of the metabolites in the 
liver and their removal from the body by the renal proximal tubule cells (RPTCs).  In 
other words, the peak metabolite concentrations and duration of exposure to the toxins 
are mostly determined by the kidney’s ability to actively remove these substances from 
the body.  Therefore, the mechanisms governing the absorption, distribution, and 
excretion of these compounds likely play a central role in their associated toxicities. 
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Two gene families expressed in the kidney and liver that mediate the transport of small 
organic anions are the Organic Anion Transporter (OAT) family and the Organic Anion 
Transporting Polypeptide (Oatp) family.  Recently, DCVC uptake by rabbit proximal 
tubules was demonstrated to be blocked by p-aminohippurate (PAH), the prototypical 
substrate for OATs.  This finding suggests the OAT family of transporters is involved in 
the absorption, distribution, and excretion of TCE metabolites (Oatps do not transport 
PAH).  In further support of this, DCVC inhibited organic anion transport mediated by 
the rabbit and human orthologs of organic anion transporter 1 (Oat1) expressed in 
heterologous cell systems. 
 
Variation in the renal elimination rate constants of the ultimate carcinogenic metabolites, 
TCA and/or DCA, is likely to be a crucial factor in physiology based pharmacokinetic 
(PBPK) modeling for sensitive populations and in risk assessment based upon such 
modeling.  Current PBPK models used in the assessment of toxicological endpoints for 
TCE exposure do not incorporate the contribution of active transport mechanisms that 
impact body compartment distribution and concentration levels, including organ-specific 
accumulation and/or secretion of TCE and its metabolites.  Therefore, the proposed 
research will quantify the contribution of active transport to the absorption and secretion 
of the acidic metabolites of TCE (TCA and DCA), as well as the metabolite DCVC, to 
increase the complexity and accuracy of PBPK models for TCE exposure. 
 
Relevance 
 
It is well known that TCA has a long plasma half-life in rodents and humans and that this 
is a major contributor to the high “area under the curve” (AUC) for TCA.  Restrictive 
binding to plasma albumen has been suggested as the molecular basis for this long half-
life.  However, recent studies have indicated that the extent of binding is less than 90% 
and hence should be non-restrictive for glomerular filtration.  An alternative explanation 
for the lack of rapid renal excretion is glomerular filtration followed by reabsorption from 
the lumen of the nephron by an active transport process.  Thus, renal organic anion 
transporters may play a significant role in determining the AUC for TCA, and hence be a 
prime determinant in the dose/response relationship for hepatocellular carcinoma.  
Knowledge of the rate constants characterizing renal transport would be helpful in 
validation of PBPK models of TCE hepatocellular carcinoma and essential in the 
identification of individuals at highest risk. 
 
Knowing which transporters are responsible for mediating the elimination and/or 
reabsorption of DCVC, TCA, and DCA would aid in the prediction and modeling of 
potential drug-xenobiotic interactions that might exacerbate or alleviate the toxic effects 
of these compounds.  Understanding the molecular basis for differing sensitivities of 
exposure between rodents and humans would aid the process of extrapolating rodent 
bioassay data to humans.  This information might also make it possible to include 
toxicogenetic parameters in risk assessment models to identify individuals/populations 
predisposed to increased risk of nephrotoxicity and hepatocarcinogenicity after TCE 
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exposure.  Expression levels of the identified transporters may even serve as useful 
biomarkers for the identification of such individuals/populations. 
 
Objective 
 
Preliminary investigations will determine the ability of unlabeled TCA, DCA, and 
DCVC to inhibit the function of cloned organic anion transporters expressed in 
Xenopus oocytes and transfected cultured mammalian cell lines.  Once potential 
transporters have been identified, their ability to mediate transport of radiolabeled 
TCA, DCA, and DCVC will be directly examined and the kinetic parameters of 
transport determined.  These observations will then be confirmed in intact tissue 
systems (i.e., kidney and liver slices) and isolated primary RPTC from mouse, rat, 
rabbit, and humans.  The impact that interindividual variation in transporter 
expression and function has on susceptibility to TCE induced renal and hepatic 
toxicity will also be examined. 
 
In order to establish the role active transport of TCA, DCA, and DCVC plays in their 
associated nephrotoxicity/hepatocarcinogenicity the following specific objectives will be 
addressed: 
 
Specific Aim 1. The identification of specific transporters controlling the systemic 
disposition of DCVC, TCA, and DCA in mouse, rat, rabbit, and human RPTC. 
 
Specific Aim 2. Characterization of mouse, rat, rabbit, and human transporter 
kinetic constants for DCVC, TCA, and DCA. 
 
Specific Aim 3. Assessment of potential drug-xenobiotic interactions for the 
mouse, rat, rabbit, and human transporter orthologs and their influence on the toxicity of 
DCVC, TCA, and DCA. 
 
Specific Aim 4. Incorporation of this information into PBPK models of TCA, 
DCA, and DCVC distribution for risk assessment purposes. 
 
Quarterly Accomplishments 
 
Work on this project has been suspended as a result of funding uncertainties.  Significant 
accomplishments to date are delineated below: 
 
Murine primary RPTC cultures: 
 
1. We have characterized urate uptake in primary murine RPTCs for use in TCE 
(TCA and DCA) risk assessment. The urate transporter is also an Slc22a 
transporter family member and thus a candidate transporter for having potential 
interactions with TCA and DCA. 
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2. Experiments determining the toxicity of DCVC to murine RPTCs in culture 
have been performed to (a) determine the appropriate sublethal toxic dose for 
exposure prior to mRNA collection for gene chip microarray analysis and (b) 
complement the data collected previously in the human primary RPTC model. 
 
Human primary RPTC cultures: 
 
3. In vitro cytotoxicity studies examining the sensitivity of hRPTCs to sub-chronic 
exposure to DCVC have been completed.  Confluent monolayers of hRPTCs 
were treated daily with 7 different concentrations of DCVC (0, 0.1, 0.3, 1, 3, 10, 
and 30 µM) for 10 days to mimic a worker exposure situation.  The resultant 
cytotoxicity was quantitated on days 1, 3, 7 and 10 by MTT assay.  Thirty µM 
DCVC produced greater than 60% toxicity within 3 days, 10 µM produced 
greater than 75% toxicity within 7 days, and 3 µM produced ~25% toxicity in 7-
10 days.  The other concentrations were without much effect over the course of 
the experiment as assayed by MTT activity.  However, some mild effects on 
respiration were noted by day 10 with 1 µM DCVC.  Finally, sub-chronic 
exposure to DCVC produced 50% cytotoxicity in hRPTCs at 7.5 µM after 10 
days.  Therefore, 0.1 and 1 µM DCVC have been selected as the low dose and 
high dose non-cytotoxic concentrations to use in experiments aimed at 
determining the gene expression changes following exposure to sub-lethal doses 
of DCVC. 
 
4. The in vitro cytotoxicity of the glutathione conjugate DCV-GSH was also 
investigated.  Similar to DCVC, DCV-GSH at 30 µM produced ~40% toxicity 
in 3 days and greater than 60% toxicity within 7 days, and 10 µM DCV-GSH 
produced ~25% toxicity in 7-10 days.  However, all other concentrations of 
DCV-GSH were without effect. 
 
5. In vitro cytotoxicity studies with chloral hydrate (CH) have been conducted.  
Confluent monolayers of hRPTCs were treated daily with 6 different 
concentrations of CH (0, 0.03, 0.1, 0.3, 1, and 3 mM) for 10 days.  Again, the 
resultant cytotoxicity was quantitated on days 1, 3, 7 and 10 by MTT assay.  
Three mM CH produced ~25-30% toxicity within 1 day and increased to 50-
60% within 7-10 days.  Other concentrations of CH were without any 
significant consistent effect.  Thus, while CH was cytotoxic, it required 1,000-
fold higher doses than DCVC (1-3 mM over 10 days). 
 
6. The metabolism of CH (1 mM) to TCE and TCA by hRPTCs in culture has 
been observed at 1, 2, 7, and 10 days.  The percent of CH converted to TCE 
varied between ~30-60% on each day and to TCA varied from ~2-4%.  Thus, 
hRPTCs can metabolize CH to TCE and TCA. 
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Performance Schedule and Status of Aims 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in he specific aims are anticipated. 
 
 
3.1.4 Effect of Genetic Variation and of Ethanol on the Formation of 
Trichloroacetic Acid, a Putative Hepatocarcinogenic Metabolite of TCE 
 
Project Director:     David McMillan, Ph.D. 
 
Executive Summary 
 
During this quarter we are continuing to collect and perform studies on chloral hydrate 
metabolism using human hepatocyte cultures. We have begun to observe some variability 
in the formation of TCA and TCE-OH, though more human samples will be required to 
determine the extent of the variability and the relationship to genotype. We are in the 
process of determining how many samples it will take to determine variability using 
power calculations using the known variability in the metabolism of ethanol. We also 
continue to detect the formation of DCA in human samples, and it appears that formation 
of this metabolite is real and not an artifact. We plan confirm its identity using GC/MS 
analysis in the next quarter. An abstract to the Society of Toxicology meeting on these 
data have been prepared. 
 
Relevance 
 
The utility of PBPK modeling of blood TCA levels as a dose metric for liver exposure to 
TCA after TCE ingestion is well accepted. Unfortunately, the relationship between TCE 
exposure and liver levels (AUC and peak concentrations [which may vary 
independently]) are complex and are very likely to show major differences among human 
sub-populations. These differences may underlie enhanced susceptibility (or resistance) 
by both genetic and environmental factors. The interaction of the genetic and 
environmental factors may further alter the relationship between applied dose of TCE and 
liver exposure to TCA. The proposed studies will be used in collaboration with projects 5 
and 6 to improve the reliability and applicability of PBPK modeling in the assessment of 
risk of humans to TCE. 
 
Objectives 
 
1. To determine the kinetic constants for conversion of CH to TCA and TCOH in 
hepatocytes from the target species, mice and rats (including the back reaction of 
TCOH to CH and TCA). 
2. To determine the kinetic constants for conversion of CH to TCA and TCOH in 
human hepatocytes. 
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3. To characterize the isoform composition of human hepatocytes by enzymic and 
DNA array technology. 
4. To determine the effect of ethanol on the redox state of hepatocytes from mice, 
rats and humans. 
5. To determine the effect of ethanol on conversion of CH to TCA and TCOH in 
hepatocytes from mice, rats and humans. 
 
Specific Aim 1. To determine the kinetic constants for conversion of CH to TCA 
and TCOH in hepatocytes from the target species, mice and rats (including the back 
reaction of TCOH to CH and TCA). 
 
Specific Aim 2. To determine the kinetic constants for conversion of CH to TCA 
and TCOH in human hepatocytes.  
 
Specific Aim 3. To characterize the isoform composition of human hepatocytes by 
enzymic and DNA array technology. 
 
Specific Aim 4. To determine the effect of ethanol on the redox state of 
hepatocytes from mice, rats and humans. 
 
Specific Aim 5. To determine the effect of ethanol on conversion of CH to TCA 
and TCOH in hepatocytes from mice, rats and humans. 
 
Quarterly Accomplishments 
 
Work on this project has been suspended as a result of funding uncertainties.  Significant 
accomplishments to date include: 
 
1. Evaluation of cryogenically-preserved human hepatocytes for chloral hydrate 
disposition and ADH/ALDH genotype. 
 
2. Development of the ability to determine all of the single nucleotide polymorphisms 
for the ADH/ALDH enzyme systems. 
 
3. Demonstrated that there is inter-individual variation in the Vmax values for TCOH 
and TCA formation, although the disposition of chloral hydrate into these two 
competing pathways is relatively constant. 
 
4. The application of cryopreserved human hepatocytes in trichloroethylene risk 
assessment has been published in the Environmental Health Perspectives (114: 
1237-1242; 2006). 
 
Performance Schedule and Status of Aims 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims are anticipated. 
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3.1.5 Presystemic Elimination of Trichloroethylene and its Interactions with 
Alcohol: How Important are They at Environmental Exposure Levels? 
 
Project Director:     James V. Bruckner, Ph.D. 
 
Executive Summary 
 
Although extremely high doses of trichloroethylene (TCE) are required to produce 
tumors in mice and rats, there is concern on the part of the EPA and others that even trace 
(i.e., environmental) levels may present a cancer risk to humans.  The human body has a 
number of processes to protect against such low level toxic insults, including first-pass, 
or presystemic elimination.  Volatile organic chemicals (VOCs) such as TCE that are 
absorbed from the gut are subject to metabolism by the liver and exhalation by the lungs, 
before they reach the arterial circulation and are distributed systemically.  It has been 
theorized, but not demonstrated experimentally, that all of low oral doses of VOCs are 
removed by presystemic elimination.  It will be necessary to develop very sensitive 
analytical techniques in order to conduct experiments with environmentally-relevant 
levels of TCE.  Demonstration [experimentally and by physiologically-based 
pharmacokinetic (PBPK) modeling], that all of low oral doses of TCE are eliminated, 
would have a profound effect on extrahepatic cancer and non-cancer risk assessments of 
TCE. 
 
Alcohol (i.e., ethanol) and a number of other compounds are known to stimulate 
formation of increased amounts of cytochrome P450 2E1 (CYP2E1) in the liver.  
CYP2E1 is the key enzyme that initiates the oxidation of low doses of TCE to potentially 
mutagenic metabolites.  Thus it is reasoned that drinkers metabolically activate a greater 
percentage of their systemically-absorbed dose of TCE to carcinogenic metabolites.  
Similarly, populations with genetically-determined elevations of CYP2E1 might also be 
anticipated to be at increased risk.  The EPA uses this reasoning in their most recent 
health risk assessment of TCE, to support their choice of the most conservative (i.e., 
linear, no-threshold) mathematical model to predict cancer risks.  Preliminary PBPK 
modeling efforts suggest that elevated CYP2E1 activity will not result increased 
metabolism of low, environmentally-relevant doses of TCE.  Every human has CYP2E1 
activity far in excess of that necessary to metabolize all of low doses.  Since all of trace 
amounts of TCE are metabolized, it is reasonable to conclude that increased metabolic 
capacity due to alcohol, drugs, genetics, etc. is inconsequential.  Laboratory experiments 
and PBPK modeling will be carried out to prove this hypothesis. 
 
Relevance 
 
As described above, this research project is directly relevant to current and proposed EPA 
regulatory standards for drinking water contamination by TCE.  The EPA concludes, 
through both its cancer and non-cancer risk assessments (EPA, 2001), that exposure to 
even minute levels of TCE is associated with low-level human risks.  It is concluded that 
certain subpopulations with genetically- or drug-induced elevations of P4502E1 (the 
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enzyme responsible for formation of toxic metabolites of TCE) will be at significant risk.  
Preliminary research with other well-metabolized chemicals indicates that this is not true.  
The proposed research with alcohol should definitively establish this for TCE.  The 
second low-dose phenomenon to be investigated here will be presystemic, or first-pass 
elimination.  The liver and lungs act in concert to eliminate ingested VOCs before they 
reach the systemic/arterial circulation.  It is postulated that virtually all of trace levels of 
TCE in drinking water are removed, before they reach and present a hazard to 
extrahepatic target organs such as the lungs and kidneys.  Experiments have been 
designed and a PBPK model will be developed in collaboration with Dr. Fisher to 
characterize the capacity of this protective mechanism under different TCE exposure 
conditions. 
 
Objectives 
 
1. Develop and validate assays of TCE and its major metabolites in biological 
samples, including blood, tissues and urine.  The assays should be sufficiently 
sensitive to utilize in animal experiments employing very low doses of TCE. 
 
2. Accurately determine the capacity and dose-dependency of presystemic 
elimination of orally-administered TCE.  Characterize the influence of dose 
and dosage regimen on the systemic disposition/effects of TCE and related 
VOCs. 
 
3. Establish the influence (or lack thereof) of ethanol on the metabolic activation 
of low oral doses of TCE.  Determine whether the ratio of the metabolites 
trichloroacetic acid (potentially carcinogenic) and trichloroethanol (non-
carcinogenic) is altered by ethanol. 
 
Specific Aim 1. To determine the capacity and dose-dependency of presystemic 
elimination of ingested TCE and to delineate the relative contribution of the liver and 
lungs.   
 
Specific Aim 2. To establish the influence (or lack thereof) of ethanol on the 
metabolic activation of environmentally-encountered doses of TCE. 
 
Specific Aim 3.  To determine whether the ratio of the metabolites trichloroacetic 
acid (TCA) (potentially carcinogenic) and trichloroethanol (TCOH) is altered by co-
ingestion of ethanol. 
 
Quarterly Accomplishments 
 
Work on this project has been suspended as a result of funding uncertainties.  Significant 
accomplishments to date are as follows: 
  
1. One of our two original Specific Aims was to establish the influence (or lack 
thereof) of ethanol on the metabolic activation of trichloroethylene (TCE), 
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including alteration of the ratio of its metabolites trichloroacetic acid (TCA) (a 
mouse carcinogen) and trichloroethanol (TCOH).  Experiments during the initial  
year of the project established that ethanol did indeed enhance the metabolism of 
relatively high doses of TCE to TCA and TCOH.  We hypothesized that induction 
of the hepatic cytochrome P450 (CYP) isozyme 2E1 (i.e., CYP2E1) would 
enhance the metabolism of high, but not low, environmentally-encountered doses 
of TCE.  Upon consideration of our results and experimental design, it became 
evident that ethanol was not only inducing CYP2E1, but altering alcohol and 
aldehyde dehydrogenases (ADH and ALDH), two enzymes responsible for  
conversion of the intermediate TCE metabolite, chloral hydrate, to TCOH and 
TCA.  Therefore, we chose to use pyridazine (PZ) rather than ethanol for the next 
phase of the project.  PZ is a potent CYP2E1 inducer, but has relatively modest  
effects on ADH and ALDH. 
 
2. In my third quarterly report for the second year of the project (Dec. 2004 – 
February 2005), I described two (2) important findings that were presented at the 
2005 Society of Toxicology national meeting:  (1) PZ pretreatment resulted in a 
dose-dependent increase in the rate of TCE elimination, a substantial decrease in 
blood TCA levels and a modest increase in TCOH levels in TCE-dosed rats.  
These alterations were pronounced in animals given 200 mg TCE/kg orally, but 
barely manifest at 10 mg TCE/kg, the lowest dosage administered.  These results 
support the aforementioned Hypothesis about a lack of influence of  CYP2E1 
induction on low TCE doses.  A gas chromatography-mass spectrometry (GC-
MS) method has just been developed that will allow us to continue these 
experiments with much lower (i.e., environmentally-relevant) TCE exposures; (2) 
The marked reduction in blood TCA levels (noted above) in CYP2E1-induced 
animals implies that liver cancer risks may be lower under such conditions. 
 
3. The primary focus of our work, during the reporting period of the project, has 
been on clarifying the mechanistic basis for the substantial decrease in blood TCA 
concentrations in PZ-induced rats. 
 
4. The existence and potential contributions of several interaction mechanisms have 
been investigated.  These experiments have yielded some interesting findings and 
are still ongoing. 
 
5. The results of one study indicate that PZ pretreatment of rats results in a 
significant increase in the rate of clearance of TCA from the bloodstream.  Half-
lives (t½) of TCA in uninduced rats given 50 mg TCA/kg iv in two experiments 
were found to be ~800 and 930 minutes.  The t½ of TCA is much longer (3,300 
minutes) when it is formed as a metabolite in TCE-dosed animals.   This indicates 
that TCA is a rate-limited metabolite of TCE.  PZ-induced rats that received 50 
mg TCA/kg iv exhibited a TCA t½ of ~240 minutes (versus the 800- and 930-
minute t½s in uninduced rats).    This phenomenon may have resulted from:  
increased metabolism of TCA to dichloroacetic acid (DCA) and/or other 
metabolites; induction/activation of organic anion transporters in the kidneys; 
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and/or displacement of TCA from plasma binding sites by PZ.   Equilibrium 
dialysis experiments have shown that PZ’s ability to displace TCA from rat 
plasma proteins is quite limited.  The highest PZ concentrations displaced only 
20% of bound TCA.  This alone cannot account for the pronounced increase in 
TCA clearance in vivo.  Experiments are currently underway to assess the 
influence of PZ on urinary elimination of TCA. 
 
6. A study is also being conducted to learn whether PZ pretreatment influences: 
metabolism of CH to TCA versus TCOH; and conversion of TCOH to TCA.  In 
the latter case, rats were given 50 mg TCOH/kg iv, and blood TCA profiles 
monitored for a period of hours.  TCA concentrations in blood were substantially 
lower over time in PZ-induced rats than in uninduced rats.  This may be due to 
decreased metabolism of TCOH to TCA and/or increased urinary excretion of 
TCA.  In vitro experiments are planned to determine whether the former occurs. 
 
Performance Schedule and Status of Aims 
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims are anticipated. 
 
 
3.1.6 PBPK Modeling of Toxic Metabolites of Trichloroethylene in Rats, Mice and 
Humans: Predicting the Health Risks Posed by Low Level Exposure to TCE 
 
Project Director:     Jeffery W. Fisher, Ph.D. 
 
Executive Summary 
 
Trichloroethylene (TCE) remains one of the most common ground water contaminants 
found in the US because of its disposal and use practices by the private sector, DOE and 
DOD.  The projected costs for remediation of TCE in the federal sector is well over $1 B.  
The health risks of TCE were recently reviewed by several scientists and published as a 
monologue in an Environmental Health Perspectives (EHP) Supplement (Vol. 108(2), 
2000).  Since the EHP publication on TCE, the US EPA released a draft ‘regulatory risk 
assessment for TCE’ to the authors of the EHP monologue and asked the authors to 
comment on their document.  In July 2002 the US EPA convened a scientific review 
panel to review their most recent draft TCE document. Physiologically based 
pharmacokinetic (PBPK) models were used as an aid in dose-response assessment (risk 
assessment) for cancer and non-cancer toxicological endpoints.  Five PBPK models were 
used on various human and rodents studies for cancer and non-cancer endpoints.  Several 
data gaps were identified as the US EPA attempted to use the PBPK models of Fisher, 
Clewell and Barton. In some cases the PBPK models were inappropriately or 
insufficiently exercised.  The objective of this project is to develop a single robust PBPK 
model for TCE for rodents and humans by incorporating new metabolic and kinetic data 
published since 1999, and by conducting limited critical metabolic and pharmacokinetic 
experiments in rodents to fill data gaps.  The refined PBPK model for TCE and 
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metabolites in laboratory animals and humans will be exercised in an appropriate manner, 
and the results will be used to reduce the uncertainties associated with assessing the 
human health risks posed by low-level environmental exposure to TCE.   
 
Much progress has been achieved over the last 5 years in understanding the quantitative 
aspects of metabolism of TCE in humans and rodents and in understanding the toxic and 
carcinogenic potential of the acid metabolites that are formed from metabolism of TCE.  
PBPK models have progressed from models that simply describing the parent chemical to 
PBPK models that contain sub models describing the formation and kinetics of 
metabolites such as trichloroacetic acid (TCA), trichloroethanol, chloral hydrate and in 
some cases, dichloroacetic acid.   Colleagues of mine and I have developed and published 
most of the PBPK models for TCE and metabolites in humans and rodents with financial 
support from the USAF, US EPA and Strategic Environmental Research and 
Development Program (SERDP).  The US EPA used early-unpublished versions of our 
most recent PBPK models for mice and humans in their current draft risk assessment 
document.   
 
Relevance 
The scientific issues related to determining the health risks posed by low levels of TCE in 
the environment are relevant to many other solvents found in water supplies.  If sound 
science and extrapolation methodology can be demonstrated for this chemical, then other 
chemicals can be evaluated in a similar manner.   This could lead to a potential saving of 
multiple millions of dollars in unnecessary clean-up costs. 
 
Objectives 
 
1. Harmonize current PBPK models used by the US EPA into one PBPK model for 
TCE and metabolites.  Incorporate newly published and unpublished data in 
humans and rodents.  New data sets include published and unpublished rat data on 
first pass metabolism of TCE from the laboratory of Dr. Jim Bruckner at the 
University of Georgia, published human and unpublished rat data on glutathione 
conjugation of TCE [(S-(1,2-Dichlorovinyl) Glutathione (DCVG)] obtained by 
Dr. Larry Lash at Wayne State University, and published Epidemiology studies 
performed in Europe, where urinary excretion of TCA was quantified.  
 
2. Conduct laboratory studies to refine PBPK model predicted dose metrics in 
laboratory animal and humans that will be used in the formulation of the final 
product of this project, namely a TCE human health risk assessment.  Determine 
the stoichiometric yield of DCVG for relevant doses of TCE in rats.  Information 
on DCVG will provide data to develop the DCVG pathway in a PBPK model for 
TCE and to offer plausible dose-metrics that can be associated with the risk of 
kidney cancer in humans.   Colleagues and I have time course data for DCVG in 
humans exposed to TCE vapors [Lash, LH, DA Putt, WT Brashear, R Abbas, J 
Parker and JW Fisher. 1999. Identification of S-(1,2-Dichlorovinyl) Glutathione 
in the Blood of Human Volunteers Exposed to Trichloroethylene. J. Toxicol. 
Environ. Health Part A, 56, 1-21].   
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3. Conduct laboratory studies to evaluate how much dichloroacetic acid (DCA) is 
formed metabolically from TCE.  This minor metabolite remains an important 
risk assessment issue because of its carcinogenic potency and the requirement that 
the US EPA account for cumulative risks.  DCA is the number one by-product 
from chlorination of water. Thus, to account for the health risks poised by TCE in 
drinking water, the health risks from exposure to DCA itself must be quantified 
and accounted for in the health risk assessment of TCE. 
 
4. Perform a cancer and non-cancer risk assessment for TCE using the harmonized 
single PBPK model for TCE and metabolites. The risk assessment will rely on 
‘mode of action’ hypotheses and theoretical assumptions for low dose 
extrapolations. Relevant human data sets will be incorporated into the analyses.  
 
Specific Aim 1. To harmonize current PBPK models used by the US EPA into one 
PBPK model for TCE and metabolites by incorporating newly published and unpublished 
data in humans and rodents. 
Specific Aim 2. To examine the metabolism of TCE in rodents with emphasis on 
the dose-dependence of conversion of TCE to DCVC. 
 
Specific Aim 3. To re-examine the dose-dependence of conversion of TCE to DCA 
in laboratory animals. 
 
Specific Aim 4. To perform a cancer and non-cancer risk assessment for TCE using 
the harmonized single PBPK model for TCE and metabolites. 
 
Quarterly Accomplishments 
 
Work on this project has been suspended as a result of funding uncertainties.  Significant 
accomplishments to date are as follows: 
 
1. Human Dichloroacetic acid PBPK model: A model structure and metabolic 
descriptions of DCA were patterned after work in our laboratory with the 
development of a PBPK model for DCA in rats and mice. The Michaelis-Menten 
affinity constant for GSTz (Km) and enzyme degradation rate (Kde) in the model 
were fixed. The initial maximum velocity of GSTz for metabolism of DCA (Vmaxc), 
the non-metabolism loss rate (Kfc), inhibition rate (kd) and oral absorption rates were 
estimated through fitting DCA blood kinetic data sets from different human clinic 
studies.  
 
Several published kinetic studies exist for DCA. Additionally, we are using new 
unpublished low dose pharmacokinetic data collected with 8 males and 8 females 
under an EPA grant at Battelle NW. These individuals were given a single iv dose 
(0.3 mg/kg) followed by a 2 mg/kg oral dose at the beginning of the study and then 
repeated14 days later.  The subjects drank 0.02 mg/kg DCA for 14 consecutive days 
between the two doses.  
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The human DCA kinetic model suggests the polymorphic forms of GSTz and oral 
absorption rates influence the kinetics of DCA. Our simulations also suggest that 
DCA is degraded by another unknown metabolic pathway as proposed in our DCA 
modeling with rats and mice. 
 
2.  Two trichloroacetic acid (TCA) modeling papers are nearly finished for submission to 
journals. One paper describes the influence of serum protein binding on the dosimetry 
of TCA in liver of mice and humans. The other paper evaluates the pharmacokinetic 
evidence that TCA is the primary metabolite responsible for liver tumors in mice. 
 
Performance Schedule and Status of Aims  
 
The performance schedule of this project is being restructured as a result of funding 
uncertainties.  No significant changes in the specific aims are anticipated. 
 
 
3.2 Environmental Epidemiology and Risk Assessment Projects 
 
3.2.1 Low Dose Radiation: Toxicological Models of Cancer Risk 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
The use of experimental animals in radiation risk estimation is especially important for 
those situations when human data are inadequate or unavailable.  This is particularly true 
for neutron exposures and low-dose rate exposures to gamma and x-ray.  The purpose of 
this project is to apply biological based models to radiation risk estimation using 
experimental data.   
 
The important questions to be answered are 1) whether or not non-cancer effects such as 
cardiovascular disease (CVD) are effected by low doses of radiation. 2) What is the 
increase in risk for a equivalent dose of alpha or neutron compared to gamma or x-ray? 3) 
Is the risk of chronic radiation exposure the same as that of acute exposure of both high 
LET (alpha, neutron) and low LET (gamma, beta, x-ray) exposures.  4) Are cancer and 
non-cancer effects present at low doses of radiation (neutron, alpha and gamma)? 
 
Relevance 
 
By comparing the two stage clonal expansion models for cancer with the in vivo 
experimental data, the investigators will not only increase understanding of cancer 
development following low-dose radiation exposure, but also add biological credibility. 
This approach will provide a method for answering the important environmental question 
of whether risks are decreased with decreasing dose-rate, a key issue for chronic radiation 
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control of workplace exposures.  Further, the effects of neutron and alpha exposure at 
low-doses is of importance to radiation workers. 
 
Objective 
 
The objective of this project is to determine the effects of dose-rate and radiation type on 
the development of various cancer types following low-dose radiation exposures. Two-
stage biologically based risk models will be used for analysis and compared with the 
results from traditional methods of analysis. Using previously validated data, assumptions 
made about the biological effects of ionizing radiation can be used in the two-stage model 
to predict dose-rate effects on the development of various cancers following low-dose 
exposures.  Additionally non-cancer effects such as cardiovascular disease will be 
estimated at low doses of radiation. 
 
Specific Aim 1. To use the large Argonne National Laboratory Janus mouse study 
to answer basic questions concerning dose-rate and radiation type effects on cancer.  This 
involves over forty thousand mice exposed acutely and chronically at several doses with 
both gamma or neutron exposures. 
 
Specific Aim 2 To use the data from new studies at the Bologna Institute of 
Oncology (Italy) on gamma exposed Spague-Dawley rats.  This data will provide for the 
estimation of low-dose effects of gamma exposures.  These studies involve both acute 
and chronic exposures. 
 
Specific Aim 3 To use this data from the Harwell Laboratory (U.K.), which 
involves alpha and beta radiation by inhalation and injection exposures to mice.  These 
studies provide an accurate comparison of the cancer effects of alpha exposure to that of 
beta. 
 
Quarterly Accomplishments 
 
Aim 1- The mouse data from Argonne labs was analyzed for gamma and neutron effects.  
This involved both acute and fractionated exposures and a manuscript is being revised 
which evaluated the effects of radiation on CVD.  A manuscript on leukemia/lymphoma 
and also solid tumors using biologically based risk models has been accepted. Currently 
effects on life-shortening are being analyzed and also the radiation effects on various 
types of hematopoietic cancers.  A manuscript on CVD in mice and both gamma and 
neutron exposures has been submitted. 
 
Aim 2 - Gamma exposed rats have been analyzed from a very large study recently 
completed in Italy.  The data provides estimates of experimental low dose effects at 0.1 
Sv from acute exposures.  Manuscripts are being prepared.  A second large study 
involving chronic exposures has been completed and the histopathology is being 
evaluated in preparation of analysis 
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Aim 3 - Dr. Hoel and Dr. Priest have completed the analysis of the beta and alpha 
exposed mouse studies from Harwell.  Lung cancer was the endpoint and the RBE 
between alpha and beta turned out to be much smaller than what is believed by the 
radiation regulators.  The analysis has mostly been completed on a second Harwell study 
involving alpha and beta exposures from radionuclide injections in mice.  These should 
further our understanding of RBE values for various cancer sites.  A paper reporting these 
results has been published.  An analysis of the same study but using injection instead of 
inhalation is near completion. 
 
Computing methods for the two stage clonal expansion model are near completion.  This 
will allow us to apply the analysis to the available animal data (Argonne, Harwell, 
Bologna) for improved cancer risk estimates. 
 
Publications 
 
Baker GS, Nakamura T, Hoel DG. Comparison of two models of cancer risk estimation: 
a statistical analysis. Eur. J. Oncol., Vol 11, 165-76 (2006) 
 
Priest ND, Hoel DG and Brooks PN. Relative Toxicity of Chronic Irradiation by 45Ca β-
particles and 242Cm ά-particles, with Respect to the Production of Lung Tumors in BA/Ca 
mice. Radiation Research, 166: 782-93, 2006. 
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
 
3.2.2 Low Dose Radiation: Epidemiological Risk Models 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
The data used for estimating health risk from low LET radiation (e.g. x-ray, gamma) has 
been obtained from the A-bomb survivor cohort.  This group, along with some cohorts of 
high dose medically exposed individual’s makes up our source of information.  Two 
important issues are of current concern: 1) Does the risk of cancer follow a linear dose-
response at low-doses?, 2) Are individuals exposed at older ages (i.e. greater than 45 
years) more susceptible to developing cancer than expected?, 3) What are the non cancer 
radiation effects? 
 
We have shown that the cancer risks at low-doses based upon the A-bomb data over 
estimates cancer risk.  We have incorporated errors in dosimetry into the analysis of 
cancer risk and are proceeding to evaluate the risk at low doses of radiation exposure. 
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Relevance 
 
Using Japanese A-bomb survivor data, the investigators seek to refine our understanding 
of the mathematical relationship between health outcomes (cancer and non cancer) data 
and exposures to low-dose radiation.  The issue of whether the relationship is linear or 
non-linear continues to be controversial.  This project will address this very important 
scientific issue. 
 
Objective 
 
The shape of the dose-response function for radiation-induced cancer and non-cancer 
effects in humans has depended primarily on data obtained from the Japanese A-bomb 
survivors. This project will re-examine these data with respect to the linearity of cancer 
risks from low dose (1-10 rem) radiation exposures. An analysis of A-bomb survivor data 
for solid tumors and leukemia indicates that there is a non-linear relationship to 
carcinogenesis following low-dose radiation exposure. Uncertainty in the dose estimates, 
including underestimation of neutrons and a relative biological effectiveness (RBE) that 
varies with dose are being incorporated into this low-dose analysis.  A comprehensive 
and focused analysis of epidemiological data from Japanese A-bomb survivors will 
greatly increased our understanding of the true epidemiological relationship between 
cancer and non-cancer risks and low-dose radiation exposure. In addition, DOE worker 
data which has been reported as providing the scientific basis for an increased 
susceptibility from exposure at older ages will be evaluated and contrasted with the A-
bomb data. 
 
Specific Aim 1. To carefully perform statistical modeling of the available 
epidemiological data from the A-bomb survivor cohort in order to increase our 
understanding of the cancer and non-cancer risks related to low-dose radiation exposure.  
Specific Aim 2. The DOE worker data from CEDER (DOE’s data repository) will 
be used to evaluate the effect of exposures at older ages and reported increased cancer 
risk following low-dose radiation exposure.  The entire set of available worker data will 
be modeled in order to evaluate the older age issue.  The results of the worker analysis 
will then be compared to the analysis of the acutely exposed A-bomb survivors. 
 
Quarterly Accomplishments 
 
The analysis of CVD risk in A-bomb survivors has been assessed.  We are in the process 
of assessing CVD risk in the analysis of animal studies as it projects to human risk.  A 
manuscript is in draft concerning cancer risk estimates from the A-bomb survivors.  This 
analysis incorporates the uncertainty in the exposure estimation. 
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Publication 
 
Baker PJ and Hoel DG.  Meta-analysis of standardized incidence and mortality rates of 
childhood leukemia in proximity to nuclear facilities.  European Journal of Cancer Care 
(in press). 
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
 
 
3.2.3 Health Risks of Low Dose Plutonium Exposure 
 
Project Director:      David G. Hoel, Ph.D. 
 
Executive Summary 
 
Human data on health risks associated with internal exposure to radionucleides (by 
inhalation and/or ingestion) is limited. With regard to plutonium exposures, there have 
been two DOE worker studies and, more recently, several studies of Russian nuclear 
workers (Mayak). One of the DOE worker cohorts (Rocky Flats) contains data that may 
be very useful in understanding the carcinogenic effects of low-dose plutonium exposure. 
In contrast to the paucity of human data, there is a considerable amount of experimental 
data related to the development of cancer in rats and dogs following plutonium 
inhalation. A statistical model of cancer risk following low-dose plutonium exposure is 
becoming increasingly important with respect to planned DOE material disposition 
activities, both domestic and international. For example, plans to eliminate surplus U.S. 
plutonium during the next two decades, through the irradiation of mixed oxide fuel and 
the conversion of a certain portion of the material to an immobilized waste form, 
represent significant program initiatives, the effects of which should be incorporated into 
evolving statistical risk models.  U.S. data will be related to prior studies of the Mayak 
workers which have consistently shown a higher level of lung, liver and bone cancer in 
comparison to U.S. workers.  Pulmonary fibrosis is also a risk from the inhalation of 
plutonium; factors related to this risk will be assessed through the analysis of available 
animal and human data. 
 
Relevance 
 
The processing and storage of plutonium requires a quantitive understanding of the health 
risks of plutonium, particularly in the low-dose range. Furthermore, DOE workers who 
may be exposed to plutonium should be monitored with a state-of-the-art medical 
surveillance program that includes the use of validated biomarkers. 
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Objectives 
 
1. The general problem we are considering is the evaluation and protection of the 
health of DOE workers in their handling of plutonium at the SRS and other DOE 
facilities. The project will develop risk models of the health effects, including non 
cancer effects, of low dose plutonium exposures and subsequently the design of 
an appropriate medical surveillance system.   
 
2. The first step is a quantitative evaluation of the human and animal data so that we 
have good productive risk models.   
 
3. We will develop a medical and environmental surveillance system which includes 
the use of urine analyses for the measurement of internal plutonium levels.  
 
Specific Aim 1 To develop human risk models for cancer and non-cancer effects 
of plutonium exposures. 
  
Specific Aim 2.  To develop a medical surveillance system for DOE workers.  This 
includes methods for the medical and environmental surveillance of the workers  
 
Quarterly Accomplishments 
 
Current data analyses are restricted to beagle dogs exposed via inhalation to plutonium-
238 and plutonium 239.  Ongoing efforts include evaluating the feasibility of pooling 
data across the two isotopes of plutonium and the two laboratories (ITRI and PNNL) that 
conducted the research,  describing methods of internal dose estimation that may be 
applied to human exposures, generation of estimates of internal dose and incidence of 
cancers and other diseases, including pulmonary fibrosis, in beagle dogs in order to 
develop risk models for humans, and apply the risk models to data on populations of 
nuclear workers to assess the applicability of animal data to humans.  The time-dependent 
dose-response models for the incidence of lung cancer and lung fibrosis after exposure to 
plutonium 238 and plutonium 239 have been completed and risk modeling is nearing 
completion.  A manuscript has been drafted and is undergoing revision.  The time-
dependent dose-response models for lung, liver and bone cancer mortality after exposure 
to plutonium 238 and plutonium 239 are underway.  A manuscript is being drafted.   
 
Performance Schedule and Status of Aims 
 
Neither the performance schedule nor the status of aims has changed. 
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3.2.4 Population Risk Studies Using Geographic Information System Technology 
 
Project Director:      Daniel Lackland, Dr.P.H. 
 
Executive Summary 
 
We have developed the infrastructure, resources and technical expertise necessary to 
conduct epidemiological assessments of population health risks using a geographical 
information system (GIS). Our sources include the following: 
 
Savannah River Region Health Information System (SRRHIS) 
The geographic cancer registry incorporates 25 counties around the Savannah River Site.  
Cancer incidence data obtained in a high quality manner is an essential component of 
epidemiological investigations. 
 
A direct link to this resource has been established in which cancer cases are 
geographically identified and incorporated in the data analysis. SRRHIS provides the 
cancer-related component of the assessment system. Cancer incidence and mortality rates 
are analyzed with respect to various aspects of population characteristics, demographic 
data and environmental exposures. 
 
Geo-coding System 
The ability to ascertain and analyze health-related, environmental, and socio-economic 
data for small areas, such as a census block, is an essential component of epidemiological 
investigation. A Geographic Information System (GIS) defines geographic study areas by 
organizing small areas such as census blocks. The system consists of computerized 
databases structured to a defined geographic area combining the tools for thematic map 
generation, proximity analysis, buffer zone identification and map overly comparisons.   
 
A critical component of any GIS is the ability to “address match” other databases into the 
system. An efficient GIS with a high match record must incorporate a system to add new 
addresses and changes, which requires an elaborate system of updates. In addition to 
collecting new data, epidemiological investigations are greatly enhanced with the use of 
existing data, saving money and time. Such databases, however, must be comprehensive 
and include multiple health outcomes, co-morbidities, indicators of socio-economic 
status, environmental exposures and population demographics and characteristics. 
 
The analytical assessment of disease patterns constitutes a critical stage in the 
investigation of the environmental etiology of disease. The assessment involves the use 
of resources such as the GIS and multiple databases. Analyses involve a complex and 
sophisticated quantitative methodology. 
 
Existing Databases 
The MUSC Environmental Biosciences Program has established access links to various 
health and environmental data bases including the SC Medicaid and Medicare data bases, 
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hospital discharge and billing data, census TIGER files, as well as data and tissue 
specimens from cohort studies such as the Evans County Heart Study.  Information from 
these databases is being used in conjunction with SRRHIS data for the epidemiological 
assessment of population health risks in the vicinity of the Savannah River Site. The 
MUSC Environmental Biosciences Program also maintains the capability to collect new 
data and tissue samples. 
 
Objectives 
 
1. To develop a comprehensive population risk assessment system and associated 
protocols. 
 
2. To conduct several epidemiology risk assessments of populations in the vicinity 
of the Savannah River Site (SRS) using the resources of the comprehensive 
system. 
 
3. To establish and maintain a state-of-the-art information system that interfaces 
with the agencies and custodians of health, environmental, geographic 
demographic and economic databases in order to provide more accurate and 
comprehensive population risk assessment. 
 
Specific Aims 
 
Specific Aim 1.  To continue to develop and enhance the Geographic Information 
System as a tool for the conduct of population risk studies. 
 
Specific Aim 2.  To continue the analysis of population cancer risks in the vicinity 
of the Savannah River Site (SRS). 
 
Specific Aim 3.  To assess population health risks in relation to specific 
environmental hazards at SRS and other DOE sites. 
 
Quarterly Accomplishments 
 
 
1. The Toxic Release Inventory has been initially analyzed, and these data as related 
to TCE sources has been plotted with particular emphasis to the Savannah River 
Region. The system has incorporated data from the US Geological Survey and 
EPA Toxic Release Inventory with a GIS application.  As an example of analyses 
currently underway, the following map depicts the distribution of all TRI 
registered sites in the SRRHIS region.  Incorporating contamination 
measurements from various sources will lead to better understanding the 
environmental state of the region. These results will be the focus of an ecological 
assessment of TCE sites and a primary focus on various cancers and cancer rates 
in the Savannah River Region. The data base is structured such that other 
conditions can be mapped with these source points.  Cancer rates by geographic 
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areas will be added to the maps in 2007. These site locations were merged with 
the water source maps during this quarter. Spatial analyses will be applied during 
the Spring. 
 
 
 
 
2. Planned manuscripts and abstracts include: 1] an assessment of population disease 
rates and the disease rates of former workers; 2] an assessment of environmental 
exposures and cancer rates; 3] the geographic comparisons of adverse outcomes 
and the availability of primary medical care; 4] cancer rates and the location of 
cancer prevention services 5] cardiovascular disease among retires SRS workers; 
6] cancer rates for former SRS workers. 
 
Performance Schedule and Status of Aims 
Neither the performance schedule nor the status of aims has changed. 
 
